This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain (COMPASS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05470608
Recruitment Status : Active, not recruiting
First Posted : July 22, 2022
Last Update Posted : August 29, 2023
Information provided by (Responsible Party):
Saol Therapeutics Inc

Brief Summary:
This is a multicenter, randomized, double-blind, placebo-controlled, single ascending dose escalation study to assess the safety and efficacy of single treatment exposure of an injectable formulation of SL-1002 for the treatment of knee pain associated with osteoarthritis. Phase A of the study will enroll 3 cohorts of 8 patients per cohort, for a total of 24 patients. Patients will be randomized to receive either SL-1002 or placebo in a 3:1 ratio within each given cohort. Phase B of the study will enroll a minimum of 92 up to a maximum of 108 patients. Patients will be randomized to receive either SL-1002 or placebo in a 3:1 ratio at the recommended dose determined from Phase A. The study period will be up to 168 days inclusive of a screening period of up to 28 days.

Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Pain Drug: SL-1002 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 132 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Escalation Study to Assess the Safety and Efficacy of SL-1002 Injectable for Treatment of Knee Pain Associated With Osteoarthritis
Actual Study Start Date : June 13, 2022
Estimated Primary Completion Date : January 2024
Estimated Study Completion Date : January 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: SL-1002
SL-1002 injectable solution, single dose
Drug: SL-1002
SL-1002 injectable solution

Placebo Comparator: Matching placebo
Matching placebo injectable solution
Drug: Placebo
Matching placebo injectable solution

Primary Outcome Measures :
  1. Occurrence of treatment emergent adverse events (TEAEs) overall [ Time Frame: Time of study drug administration to end of study visit (day 168) ]
    TEAE timepoints will be observed from the time point of administration of total dose until end of study visit (day 168)

  2. Improvement of knee pain [ Time Frame: Change from baseline to Month 3 in 11 point NRS score ]
    Change in weekly average daily pain intensity via Numeric Rating Scale (NRS) score at Month 3

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients 35 years of age or older, with a Body Mass Index (BMI) of 18.0 to 40.0 kg/m2 and a total body weight of ≥50.0 kg for males and ≥45.5 kg for females.
  2. Patients with chronic knee pain resulting from osteoarthritis for greater than 6 months prior to study Screening Visit 1 that interferes with functional activities (e.g., ambulation, prolonged standing, etc.).
  3. Patients currently experiencing continued pain despite receiving at least 3 months of conservative treatments, inclusive of activity modification, home exercise, protective weight bearing, and/or use of analgesics (e.g., acetaminophen or NSAIDs).
  4. Patients with a baseline average pain score of ≥ 6 on an 11-point NRS scale as "usual level of pain over the past 24 hours during weight-bearing activities" for the index knee at Screening. The baseline average pain score is computed by finding the mean of the daily NRS pain intensity scores reported during the 7-day run in period.
  5. Patients with Kellgren-Lawrence Grade 2 (mild) or Grade 3 (moderate) radiologically confirmed osteoarthritis (via x-ray/MRI/CT) within 6 months of study Screening Visit 1.
  6. Patients with a baseline Knee Injury and Osteoarthritis Outcome Score (KOOS) pain subscale score ≥ 19 and ≤ 67 in the index knee.
  7. Patients taking analgesics, inclusive of membrane stabilizers (e.g., Neurontin/gabapentin) and/or antidepressants (e.g., Cymbalta/duloxetine), for osteoarthritis associated knee pain must be on a stable dose for at least 6 weeks prior to study Screening Visit 1. Patients must agree to not alter the dose of analgesics for the duration of the study without prior approval from the Investigator.
  8. Female patients of childbearing potential who are sexually active with a male partner must be willing to use one of the following acceptable contraceptive methods throughout the study and for 30 days after the last study drug administration:

    1. Intra-uterine contraceptive device placed at least 4 weeks prior to study drug administration;
    2. Male condom with intravaginally applied spermicide starting at least 21 days prior to study drug administration;
    3. Hormonal contraceptives starting at least 4 weeks prior to study drug administration must agree to use the same hormonal contraceptive throughout the study;
    4. Sterile male partner (vasectomized since at least 6 months).
  9. Female patients of non-childbearing potential as defined below:

    1. Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause).
    2. Pre-menopausal females with one of the following:

      • Documented tubal ligation
      • Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion
      • Hysterectomy
      • Documented bilateral oophorectomy.
  10. Patients must agree to see one treating physician (study Investigator) for knee pain treatment for study duration.
  11. Patients who have a positive response to a single genicular nerve block of the index knee using 1.5 - 3mL of lidocaine 2% solution administration to the genicular nerves planned for treatment in each cohort (0.5mL per nerve). A positive response to the qualifying lidocaine prognostic block is defined as ≥ 80% pain reduction within 60 minutes of receiving the lidocaine injections and ≥ 80% pain relief for a duration of at least 60 minutes as documented on a standardized 6-hour pain log.
  12. Patients must be able to understand and be able to complete all assessments associated with the study outcome measures.
  13. Patients must be able to understand the informed consent and be willing to provide written informed consent. Patients must be able to comply with the requirements of the protocol for the entire duration of the study.

Exclusion Criteria:

1. Patients with evidence of inflammatory arthritis (e.g., rheumatoid arthritis) or any other systemic inflammatory condition (e.g., gout, pseudogout). 2. Current diagnosis of fibromyalgia. 3. Patients with evidence of neuropathic pain affecting the index knee. 4. Patients with prior or planned lower limb amputation. 5. Patients who have received an intra-articular steroid injection into the index knee within 90 days of study Screening Visit 1. 6. Patients who have received hyaluronic acid injection, Platelet Rich Plasma (PRP), stem cell or arthroscopic debridement/lavage injection into the index knee within 180 days of study Screening Visit

  • Patients who have received prior radiofrequency ablation or any other neurolytic procedure of the genicular nerves of the index knee within 1 year of study Screening Visit 1.
  • Patients who have received prior partial, resurfacing, or total knee arthroplasty of the index knee (residual hardware).
  • Patients with clinically significant ligamentous laxity of the index knee as per Investigator discretion.
  • Patients with clinically significant valgus/varus deformities or evidence of pathology (other than osteoarthritis of the knee) that materially affects gait or function of the index knee or is the underlying cause of the knee pain and/or functional limitations.
  • Patients who are extremely thin and those with minimal subcutaneous tissue thickness that could place the patient at risk of a chemical skin burn, at the discretion of the Investigator.
  • Patients with a pending or active compensation claim, litigation or disability remuneration (possibility of secondary gain).
  • Patients with chronic pain associated with significant psychosocial dysfunction.
  • Patients with a Patient Health Questionnaire - 9 (PHQ-9) score of >10 (indicative of a state of moderate depression).
  • Patients with a systemic infection, active joint infection, or localized infection at the planned needle entry sites (patient may be considered for inclusion once infection is resolved).
  • Patients with history of uncontrolled coagulopathy or unexplained or uncontrollable bleeding that cannot be corrected, and patients with coagulopathy or who are being treated with anticoagulants.
  • Patients with moderate to severe hepatic impairment or moderate to severe renal impairment.
  • Identifiable anatomical variability that would materially alter the procedure as described in the protocol.
  • Patients currently prescribed opioid medications at a dose of >50 daily morphine equivalents.
  • Patients with uncontrolled immunosuppression (e.g., AIDs, cancer, diabetes) as per Investigator discretion.
  • Female patients who are pregnant or planning to become pregnant during the duration of the study.
  • Female patients who are breast-feeding.
  • Patients who are unable or unwilling to comply with the requirements of the protocol.
  • Patients taking any of the following concurrent medications/over-the counter products (refer to Appendix 8 in full protocol for a list of applicable medications): c. Probenecid or other organic anion transporter (OAT3) inhibitors. d. Inhibitors of CYP2E1, such as disulfiram.
  • Patients with known allergies or hypersensitivity to iodinated contrast medium and gadolinium-based contrast medium. Known allergies or hypersensitivity to phenol and/or lidocaine and/or their excipients.
  • Patients with a documented history or evidence of alcohol or drug abuse within 1 year of study screening visit 1.
  • Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days of study Screening Visit 1, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
  • Patients with clinically significant ECG abnormalities or vital sign abnormalities at during study Screening Visit 1. Patients with ECG or vital sign abnormalities deemed nonclinically significant or unlikely to result in clinical compromise by the Principal Investigator may be considered for study inclusion.
  • Patients with clinically significant laboratory results (as judged by the Principal Investigator).
  • Any condition, in the opinion of the Principal Investigator, that may pose a significant risk to the patient, confound the results of the study or interfere significantly with the patient's participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05470608

Layout table for location information
United States, Colorado
Denver Spine & Pain Institute
Greenwood Village, Colorado, United States, 80111
United States, District of Columbia
International Spine, Pain & Performance Center
Washington, District of Columbia, United States, 20006
United States, Florida
Prime Medical Research
Coral Gables, Florida, United States, 33134
Conquest Research
Winter Park, Florida, United States, 32789
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New Jersey
Cooper Neurological Institute
Camden, New Jersey, United States, 08103
United States, North Carolina
Center for Clinical Research
Winston-Salem, North Carolina, United States, 27103
United States, Oregon
Pacific Sports and Spine
Eugene, Oregon, United States, 97404
United States, Pennsylvania
University Orthopedics Center
Altoona, Pennsylvania, United States, 16602
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Texas
Institute of Precision Pain Medicine
Corpus Christi, Texas, United States, 78414
Precision Spine Care
Tyler, Texas, United States, 75701
United States, Utah
University of Utah School of Medicine
Salt Lake City, Utah, United States, 84108
United States, Virginia
Virginia iSpine Physicians
Richmond, Virginia, United States, 23235
Sponsors and Collaborators
Saol Therapeutics Inc
Layout table for additonal information
Responsible Party: Saol Therapeutics Inc Identifier: NCT05470608    
Other Study ID Numbers: 1010-01
First Posted: July 22, 2022    Key Record Dates
Last Update Posted: August 29, 2023
Last Verified: August 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases